The evolution of antipsychotic switch and polypharmacy in natural practice - A longitudinal perspective

Schizophrenia Research

Volumn 130, Issue 1-3, 2011, Pages 40-46

  Tsutsumi, Chisa ^a   Uchida, Hiroyuki ^a,b,c   Suzuki, Takefumi ^a   Watanabe, Koichiro ^a,d   Takeuchi, Hiroyoshi ^a,b,d   Nakajima, Shinichiro ^a,c,e   Kimura, Yoshie ^b,c   Tsutsumi, Yuichiro ^f   Ishii, Koichi ^d   Imasaka, Yasushi ^a,g   Kapur, Shitij ^h  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Department of Psychiatry   (Japan)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d Ohizumi Hospital   (Japan)

^e UNIVERSITY OF TORONTO   (Canada)

^f Ongata Hospital   (Japan)

^g Ohizumi Mental Clinic   (Japan)

^h KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotic; Dose; Polypharmacy; Prescription; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MONOTHERAPY; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SCHIZOPHRENIA; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JAPAN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; POLYPHARMACY; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 79960335818     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.05.013     Document Type: Article

References (37)

1. Argo T.R., Crismon M.L., Miller A.L., Moore T.A., Bendele S.D., Suehs B. Texas Medication Algorithm Project Procedural Manual: Schizophrenia Algorithm 2007, The Texas Department of State Health services.
2. Bigos K.L., Pollock B.G., Coley K.C., Miller D.D., Marder S.R., Aravagiri M., Kirshner M.A., Schneider L.S., Bies R.R. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008, 48:157-165.
3. Bradford L.D. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002, 3:229-243.
4. Buchanan R.W., Kreyenbuhl J., Kelly D.L., Noel J.M., Boggs D.L., Fischer B.A., Himelhoch S., Fang B., Peterson E., Aquino P.R., Keller W. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2009, 36:71-93.
5. Chen R.S., Nadkarni P.M., Levin F.L., Miller P.L., Erdos J., Rosenheck R.A. Using a computer database to monitor compliance with pharmacotherapeutic guidelines for schizophrenia. Psychiatr Serv 2000, 51:791-794.
6. Correll C.U., Rummel-Kluge C., Corves C., Kane J.M., Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009, 35:443-457.
7. Ito H., Koyama A., Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry 2005, 187:243-247.
8. Japanese Society of Psychiatry and Neurology Treatment Guidelines for Schizophrenia 2008, Igaku Shoin, Tokyo, [in Japanese]. the second edition.
9. Jeste D.V., Caligiuri M.P., Paulsen J.S., Heaton R.K., Lacro J.P., Harris M.J., Bailey A., Fell R.L., McAdams L.A. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995, 52:756-765.
10. Kane J.M., Correll C.U., Goff D.C., Kirkpatrick B., Marder S.R., Vester-Blokland E., Sun W., Carson W.H., Pikalov A., Assuncao-Talbott S. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 2009, 70:1348-1357.
11. Kapur S., Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:1081-1090.
12. Kinon B.J., Kane J.M., Johns C., Perovich R., Ismi M., Koreen A., Weiden P. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 1993, 29:309-314.
13. Koen L., Magni P., Niehaus D.J., le Roux A. Antipsychotic prescription patterns in Xhosa patients with schizophrenia or schizoaffective disorder. Afr J Psychiatry 2008, 11:287-290.
14. Lee B., Walker V. Polypharmacy as the initial second-generation antipsychotic treatment. Psychiatr Serv 2008, 59:717.
15. Lehman A.F., Lieberman J.A., Dixon L.B., McGlashan T.H., Miller A.L., Perkins D.O., Kreyenbuhl J. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004, 161:1-56.
16. Lemmens P., Brecher M., Van Baelen B. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand 1999, 99:160-170.
17. Leslie D.L., Rosenheck R.A. Adherence of schizophrenia pharmacotherapy to published treatment recommendations: patient, facility, and provider predictors. Schizophr Bull 2004, 30:649-658.
18. Pandurangi A.K., Dalkilic A. Polypharmacy with second-generation antipsychotics: a review of evidence. J Psychiatr Pract 2008, 14:345-367.
19. Procyshyn R.M., Honer W.G., Wu T.K., Ko R.W., McIsaac S.A., Young A.H., Johnson J.L., Barr A.M. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 2010, 71:566-573.
20. Rajji T.K., Uchida H., Ismail Z., Ng W., Mamo D.C., Remington G., Pollock B.G., Mulsant B.H. Clozapine and global cognition in schizophrenia. J Clin Psychopharmacol 2010, 30:431-436.
21. Ray W.A., Chung C.P., Murray K.T., Hall K., Stein C.M. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009, 360:225-235.
22. Rettenbacher M.A., Hofer A., Eder U., Hummer M., Kemmler G., Weiss E.M., Fleischhacker W.W. Compliance in schizophrenia: psychopathology, side effects, and patients' attitudes toward the illness and medication. J Clin Psychiatry 2004, 65:1211-1218.
23. Santone G., Bellantuono C., Rucci P., Picardi A., Preti A., de Girolamo G. Patient characteristics and process factors associated with antipsychotic polypharmacy in a nationwide sample of psychiatric inpatients in Italy. Pharmacoepidemiol Drug Saf 2011, 20:441-449.
24. Sernyak M.J., Rosenheck R. Clinicians' reasons for antipsychotic coprescribing. J Clin Psychiatry 2004, 65:1597-1600.
25. Sernyak M.J., Dausey D., Desai R., Rosenheck R. Prescribers' nonadherence to treatment guidelines for schizophrenia when prescribing neuroleptics. Psychiatr Serv 2003, 54:246-248.
26. Stahl S.M., Grady M.M. High-cost use of second-generation antipsychotics under California's Medicaid program. Psychiatr Serv 2006, 57:127-129.
27. Suzuki T., Uchida H., Watanabe K., Nakajima S., Nomura K., Takeuchi H., Tanabe A., Yagi G., Kashima H. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Hum Psychopharmacol 2008, 23:455-463.
28. Takeuchi H., Uchida H., Suzuki T., Watanabe K., Kashima H. Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: one-year follow-up study. Psychiatry Clin Neurosci 2010, 64:104-106.
29. Uchida H., Mamo D.C. Predicting age-specific dosing of antipsychotics. Clin Pharmacol Ther 2009, 86:360-362.
30. Uchida H., Suzuki T., Tanaka K.F., Watanabe K., Yagi G., Kashima H. Recurrent episodes of perceptual alteration in patients treated with antipsychotic agents. J Clin Psychopharmacol 2003, 23:496-499.
31. Uchida H., Suzuki T., Mamo D.C., Mulsant B.H., Tanabe A., Inagaki A., Watanabe K., Yagi G., Tomita M. Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1,418 patients in Japan. Am J Geriatr Psychiatry 2008, 16:584-593.
32. Uchida H., Kapur S., Mulsant B.H., Graff-Guerrero A., Pollock B.G., Mamo D.C. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. Am J Geriatr Psychiatry 2009, 17:255-263.
33. Uchida H., Mamo D.C., Mulsant B.H., Pollock B.G., Kapur S. Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry 2009, 70:397-405.
34. Uchida H., Suzuki T., Mamo D.C., Mulsant B.H., Kikuchi T., Takeuchi H., Tomita M., Watanabe K., Yagi G., Kashima H. Benzodiazepine and antidepressant use in elderly patients with anxiety disorders: a survey of 796 outpatients in Japan. J Anxiety Disord 2009, 23:477-481.
35. Uchida H., Suzuki T., Takeuchi H., Arenovich T., Mamo D.C. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis 2009, Schizophr Bull.
36. World Health Organization The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines 1992, WHO, Geneva.
37. Xiang Y.T., Weng Y.Z., Leung C.M., Tang W.K., Ungvari G.S. Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia. Pharmacopsychiatry 2007, 40:47-52.